Success Metrics

Clinical Success Rate

83.3%

Based on 50 completed trials

Completion Rate

83%(50/60)

Active Trials

1(1%)

Results Posted

50%(25 trials)

Terminated

10(14%)

Phase Distribution

Ph phase_3

32%

Ph phase_1

10%

Ph phase_4

25%

Ph phase_2

18%

Ph not_applicable

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution65 total trials

Phase 1Safety & dosage

7(10.8%)

Phase 2Efficacy & side effects

13(20.0%)

Phase 3Large-scale testing

23(35.4%)

Phase 4Post-market surveillance

18(27.7%)

N/ANon-phased studies

4(6.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

79.4%

50 of 63 finished

Non-Completion Rate

20.6%

13 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(50)

Terminated(13)

Other(8)

Detailed Status

Completed50

Terminated10

unknown8

Withdrawn3

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 4

Trials by Phase

Phase 17 (10.8%)

Phase 213 (20.0%)

Phase 323 (35.4%)

Phase 418 (27.7%)

N/A4 (6.2%)

Trials by Status

unknown811%

terminated1014%

withdrawn34%

completed5069%

recruiting11%

Recent Activity

1 active trials

Showing 5 of 72

completed

Clinical Trials (72)

Showing 20 of 72 trialsScroll for more

NCT02847624

Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD

Completed

NCT06506994Phase 1

A Study of HRS-9057 in Patients With Heart Failure and Volume Overload

Completed

NCT07166783Phase 1

Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial Protocol

Completed

NCT07166887Phase 1

Phase I Study Multi Dose of 7.5mg Tolvaptan in Health Male

Completed

NCT03406286

Samsca PMS in ADPKD Patients

Completed

NCT00664014Phase 2

A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia

Completed

NCT01733134Phase 3

Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE)

Withdrawn

NCT03255226Phase 3

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload

Completed

NCT06171100

Low-dose Tolvaptan for Inpatient Hyponatraemia.

Recruiting

NCT02964273Phase 3

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Completed

NCT03541447Phase 2

Tolvaptan-Octreotide LAR Combination in ADPKD

Completed

NCT05569655Not Applicable

Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH

Unknown

NCT03949894Phase 4

Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease

Completed

NCT05408104

Postoperative Tolvaptan Use in Left Ventricular Assist Device Implantation Patients

Completed

NCT02476409Phase 4

Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders

Completed

NCT01552590Phase 4

Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites

Terminated

NCT01214421Phase 3

Tolvaptan Extension Study in Participants With ADPKD